PD-L1 IHC 28-8 PHARMDX (Non-Squamous Indication)

Immunohistochemistry Assay, Antibody, Programmed Death-ligand 1

FDA Premarket Approval P150025 S002

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for the dakolink software version 4. 1 update for the pd-l1 ihc 28-8 pharmdx (non-squamous, non-small cell lung cancer indication).

DevicePD-L1 IHC 28-8 PHARMDX (Non-Squamous Indication)
Classification NameImmunohistochemistry Assay, Antibody, Programmed Death-ligand 1
Generic NameImmunohistochemistry Assay, Antibody, Programmed Death-ligand 1
ApplicantDAKO NORTH AMERICA, INC.
Date Received2016-08-19
Decision Date2016-12-01
PMAP150025
SupplementS002
Product CodePLS
Advisory CommitteePathology
Supplement TypeReal-time Process
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address DAKO NORTH AMERICA, INC. 6392 Via Real carpinteria, CA 93013

Supplemental Filings

Supplement NumberDateSupplement Type
P150025Original Filing
S015 2022-06-17 30-day Notice
S014 2021-07-12 Normal 180 Day Track
S013 2019-12-16 Panel Track
S012
S011 2019-02-15 30-day Notice
S010 2018-12-21 30-day Notice
S009 2018-03-12 30-day Notice
S008 2017-12-26 30-day Notice
S007
S006 2017-04-17 30-day Notice
S005 2016-12-29 Normal 180 Day Track No User Fee
S004 2016-12-27 Real-time Process
S003 2016-12-22 Panel Track
S002 2016-08-19 Real-time Process
S001 2016-07-07 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.